Cargando…
Optimising preoperative risk stratification tools for prostate cancer using mpMRI
PURPOSE: To improve preoperative risk stratification for prostate cancer (PCa) by incorporating multiparametric MRI (mpMRI) features into risk stratification tools for PCa, CAPRA and D’Amico. METHODS: 807 consecutive patients operated on by robot-assisted radical prostatectomy at our institution dur...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811593/ https://www.ncbi.nlm.nih.gov/pubmed/28986636 http://dx.doi.org/10.1007/s00330-017-5031-5 |
_version_ | 1783299892508098560 |
---|---|
author | Reisæter, Lars A. R. Fütterer, Jurgen J. Losnegård, Are Nygård, Yngve Monssen, Jan Gravdal, Karsten Halvorsen, Ole J. Akslen, Lars A. Biermann, Martin Haukaas, Svein Rørvik, Jarle Beisland, Christian |
author_facet | Reisæter, Lars A. R. Fütterer, Jurgen J. Losnegård, Are Nygård, Yngve Monssen, Jan Gravdal, Karsten Halvorsen, Ole J. Akslen, Lars A. Biermann, Martin Haukaas, Svein Rørvik, Jarle Beisland, Christian |
author_sort | Reisæter, Lars A. R. |
collection | PubMed |
description | PURPOSE: To improve preoperative risk stratification for prostate cancer (PCa) by incorporating multiparametric MRI (mpMRI) features into risk stratification tools for PCa, CAPRA and D’Amico. METHODS: 807 consecutive patients operated on by robot-assisted radical prostatectomy at our institution during the period 2010–2015 were followed to identify biochemical recurrence (BCR). 591 patients were eligible for final analysis. We employed stepwise backward likelihood methodology and penalised Cox cross-validation to identify the most significant predictors of BCR including mpMRI features. mpMRI features were then integrated into image-adjusted (IA) risk prediction models and the two risk prediction tools were then evaluated both with and without image adjustment using receiver operating characteristics, survival and decision curve analyses. RESULTS: 37 patients suffered BCR. Apparent diffusion coefficient (ADC) and radiological extraprostatic extension (rEPE) from mpMRI were both significant predictors of BCR. Both IA prediction models reallocated more than 20% of intermediate-risk patients to the low-risk group, reducing their estimated cumulative BCR risk from approximately 5% to 1.1%. Both IA models showed improved prognostic performance with a better separation of the survival curves. CONCLUSION: Integrating ADC and rEPE from mpMRI of the prostate into risk stratification tools improves preoperative risk estimation for BCR. KEY POINTS: • MRI-derived features, ADC and EPE, improve risk stratification of biochemical recurrence. • Using mpMRI to stratify prostate cancer patients improves the differentiation between risk groups. • Using preoperative mpMRI will help urologists in selecting the most appropriate treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00330-017-5031-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5811593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-58115932018-02-23 Optimising preoperative risk stratification tools for prostate cancer using mpMRI Reisæter, Lars A. R. Fütterer, Jurgen J. Losnegård, Are Nygård, Yngve Monssen, Jan Gravdal, Karsten Halvorsen, Ole J. Akslen, Lars A. Biermann, Martin Haukaas, Svein Rørvik, Jarle Beisland, Christian Eur Radiol Urogenital PURPOSE: To improve preoperative risk stratification for prostate cancer (PCa) by incorporating multiparametric MRI (mpMRI) features into risk stratification tools for PCa, CAPRA and D’Amico. METHODS: 807 consecutive patients operated on by robot-assisted radical prostatectomy at our institution during the period 2010–2015 were followed to identify biochemical recurrence (BCR). 591 patients were eligible for final analysis. We employed stepwise backward likelihood methodology and penalised Cox cross-validation to identify the most significant predictors of BCR including mpMRI features. mpMRI features were then integrated into image-adjusted (IA) risk prediction models and the two risk prediction tools were then evaluated both with and without image adjustment using receiver operating characteristics, survival and decision curve analyses. RESULTS: 37 patients suffered BCR. Apparent diffusion coefficient (ADC) and radiological extraprostatic extension (rEPE) from mpMRI were both significant predictors of BCR. Both IA prediction models reallocated more than 20% of intermediate-risk patients to the low-risk group, reducing their estimated cumulative BCR risk from approximately 5% to 1.1%. Both IA models showed improved prognostic performance with a better separation of the survival curves. CONCLUSION: Integrating ADC and rEPE from mpMRI of the prostate into risk stratification tools improves preoperative risk estimation for BCR. KEY POINTS: • MRI-derived features, ADC and EPE, improve risk stratification of biochemical recurrence. • Using mpMRI to stratify prostate cancer patients improves the differentiation between risk groups. • Using preoperative mpMRI will help urologists in selecting the most appropriate treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00330-017-5031-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-10-06 2018 /pmc/articles/PMC5811593/ /pubmed/28986636 http://dx.doi.org/10.1007/s00330-017-5031-5 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Urogenital Reisæter, Lars A. R. Fütterer, Jurgen J. Losnegård, Are Nygård, Yngve Monssen, Jan Gravdal, Karsten Halvorsen, Ole J. Akslen, Lars A. Biermann, Martin Haukaas, Svein Rørvik, Jarle Beisland, Christian Optimising preoperative risk stratification tools for prostate cancer using mpMRI |
title | Optimising preoperative risk stratification tools for prostate cancer using mpMRI |
title_full | Optimising preoperative risk stratification tools for prostate cancer using mpMRI |
title_fullStr | Optimising preoperative risk stratification tools for prostate cancer using mpMRI |
title_full_unstemmed | Optimising preoperative risk stratification tools for prostate cancer using mpMRI |
title_short | Optimising preoperative risk stratification tools for prostate cancer using mpMRI |
title_sort | optimising preoperative risk stratification tools for prostate cancer using mpmri |
topic | Urogenital |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811593/ https://www.ncbi.nlm.nih.gov/pubmed/28986636 http://dx.doi.org/10.1007/s00330-017-5031-5 |
work_keys_str_mv | AT reisæterlarsar optimisingpreoperativeriskstratificationtoolsforprostatecancerusingmpmri AT futtererjurgenj optimisingpreoperativeriskstratificationtoolsforprostatecancerusingmpmri AT losnegardare optimisingpreoperativeriskstratificationtoolsforprostatecancerusingmpmri AT nygardyngve optimisingpreoperativeriskstratificationtoolsforprostatecancerusingmpmri AT monssenjan optimisingpreoperativeriskstratificationtoolsforprostatecancerusingmpmri AT gravdalkarsten optimisingpreoperativeriskstratificationtoolsforprostatecancerusingmpmri AT halvorsenolej optimisingpreoperativeriskstratificationtoolsforprostatecancerusingmpmri AT akslenlarsa optimisingpreoperativeriskstratificationtoolsforprostatecancerusingmpmri AT biermannmartin optimisingpreoperativeriskstratificationtoolsforprostatecancerusingmpmri AT haukaassvein optimisingpreoperativeriskstratificationtoolsforprostatecancerusingmpmri AT rørvikjarle optimisingpreoperativeriskstratificationtoolsforprostatecancerusingmpmri AT beislandchristian optimisingpreoperativeriskstratificationtoolsforprostatecancerusingmpmri |